Global PROTAC Toolbox for Degrading BCR–ABL Overcomes Drug-Resistant Mutants and Adverse Effects
Yiqing Yang(Tsinghua University), Yu Rao(Soochow University), Qinjie Weng(ZheJiang Institute For Food and Drug Control), Xiuyun Sun(Tsinghua University), Yonghui Sun(Tsinghua University), Hongying Gao(Tsinghua University), Yueping Qiu(Zhejiang University)
Cited by 91
Related Papers
PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions
|Journal of Hematology & Oncology|2020|400
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353